- Home
- ELVN vs EFC Comparison
ELVN vs EFC Comparison
Compare ELVN & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- EFC
- Stock Information
- Founded
- ELVN 2016
- EFC 2007
- Country
- ELVN United States
- EFC United States
- Employees
- ELVN N/A
- EFC N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- EFC Real Estate
- Sector
- ELVN Health Care
- EFC Finance
- Exchange
- ELVN Nasdaq
- EFC Nasdaq
- Market Cap
- ELVN 1.2B
- EFC 1.4B
- IPO Year
- ELVN 2020
- EFC 2010
- Fundamental
- Price
- ELVN $19.02
- EFC $13.23
- Analyst Decision
- ELVN Strong Buy
- EFC Strong Buy
- Analyst Count
- ELVN 5
- EFC 7
- Target Price
- ELVN $41.20
- EFC $14.46
- AVG Volume (30 Days)
- ELVN 489.5K
- EFC 1.4M
- Earning Date
- ELVN 11-12-2025
- EFC 11-05-2025
- Dividend Yield
- ELVN N/A
- EFC 11.80%
- EPS Growth
- ELVN N/A
- EFC N/A
- EPS
- ELVN N/A
- EFC 1.24
- Revenue
- ELVN N/A
- EFC $312,485,000.00
- Revenue This Year
- ELVN N/A
- EFC N/A
- Revenue Next Year
- ELVN $20.05
- EFC $7.92
- P/E Ratio
- ELVN N/A
- EFC $10.67
- Revenue Growth
- ELVN N/A
- EFC 10.76
- 52 Week Low
- ELVN $13.30
- EFC $11.12
- 52 Week High
- ELVN $30.03
- EFC $14.40
- Technical
- Relative Strength Index (RSI)
- ELVN 44.06
- EFC 38.63
- Support Level
- ELVN $18.01
- EFC $13.40
- Resistance Level
- ELVN $20.30
- EFC $13.94
- Average True Range (ATR)
- ELVN 1.11
- EFC 0.19
- MACD
- ELVN -0.16
- EFC -0.08
- Stochastic Oscillator
- ELVN 30.70
- EFC 8.33
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About EFC Ellington Financial Inc.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.